Belimumab for autoimmune hepatitis
Part of Digestive system, Immune system & allergy clinical trials.
This trial tests a drug called belimumab for people with autoimmune hepatitis that is not well controlled. It aims to see if adding belimumab to your current treatment can help reduce liver inflammation.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with autoimmune hepatitis for at least 6 months.
- You have active liver inflammation (elevated ALT) or have normal ALT but are on stable immunosuppression.
- You are currently taking corticosteroids or other immunosuppressants (like azathioprine, mycophenolate, or purinethol) for your hepatitis.
- You do not have other liver diseases like hepatitis B or C, or fatty liver disease.
- You do not have advanced liver disease (like severe cirrhosis).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new medication called inebilizumab for people with autoimmune hepatitis (a condition where the body's immune system attacks the liver) who haven't responded well to standard treatments or can't tolerate them. The study aims to see if this new drug can help control liver inflammation and reduce the need for high-dose steroids.
This test compares two medicines—azathioprine and mycophenolate mofetil (MMF)—to see which is better at putting autoimmune hepatitis into remission without using steroids first. It is for people who have just been diagnosed and haven't started treatment yet.
This study is looking at specific immune cells (T cells) in the blood of people with autoimmune hepatitis (AIH) to better understand the disease. If you have untreated AIH and meet certain criteria, you may be able to participate.
This study follows people with autoimmune hepatitis (a condition where the immune system attacks the liver) and requires key blood test results at diagnosis. It may help doctors better understand this disease and how it progresses in patients in China.
This study looks at factors that help predict how well people with autoimmune hepatitis respond to treatment. It is for patients who are newly diagnosed or have not had treatment for at least 3 months, and who have had a liver biopsy to confirm the diagnosis.
This study tests whether a medicine called belimumab (Benlysta) works better for people diagnosed with lupus in the last 2 years. It aims to slow down the disease before it causes lasting organ damage.
Hear when a new Autoimmune Hepatitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.